Inhalation Sciences receives new order worth over 2 million SEK from major China inhaled pharma co.
(Stockholm October 19, 2021) Inhalation Sciences AB (ISAB) has received a new order worth 202 KEUR (2.025 MSEK) from a major inhaled pharma company in China specializing in asthma and COPD treatments for the global market. The order is for ISAB’s PreciseInhale® aerosol generating platform and its in vitro lung simulation module DissolvIt®.
The comprehensive new order covers installation, tech transfer, training and service and support for ISAB’s entire PreciseInhale® platform - plus its in vitro lung simulation module DissolvIt®. DissolvIt® is widely recognized as being a leading solution in the field of high-precision, predictive in vitro in vivo correlation (IVIC) data, reducing risk and identifying strong drug candidates very early in the development process – a major competitive advantage for inhaled drug developers.
ISAB CEO Manoush Masarrat: “China is one of the largest, most innovative and most high-potential markets in the world for inhaled therapies. We are very proud that our technology has been chosen by one of this market’s major players. This is a hugely important sale for ISAB and we look forward to continuing our collaboration with this new customer in this vital and exciting market.”
For more information on Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About Inhalations Sciences Sweden AB (publ)
Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.
The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on October 19, 1030, 2021.
Tags: